Skip to main content

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report



The prevalence of EGFR/ALK co-alterations in patients with NSCLC was low. The several previous studies focused on the simultaneous occurrence of EGFR mutations and ALK rearrangements in a unifocal lung cancer. However, the incidence of multifocal pulmonary adenocarcinomas was increasingly encountered in clinical practice, due to the increased availability and improvement of the thoracic imaging. The clinical relevance of EGFR/ALK co-alterations in multifocal adenocarcinomas required detailed investigation as well.

Case presentation

We present the case of a 57-year-old woman with solid nodule in the left upper lung and a ground glass nodule in the left lower lobe, who underwent radical operation. Pathological examination confirmed multifocal adenocarcinoma, molecular tests revealed that the left upper lung lesion was positive for ALK rearrangement but the left lower lobe displayed EGFR mutation positive separately. The patient pulmonary lesions were well controlled by adjuvant chemotherapy and radiation therapy. When brain metastases occurred, EGFR-TKI was not effective after firstly administration, while subsequent ALK inhibitors were efficient. We retrospective evaluated the oncogenic status of metastatic lymph nodes and found that the driver gene was ALK rearrangement rather than EGFR mutation.


The status of the oncogenic mutations in lymph node metastasis may provide some effective hints for metastasis lesion in other organ or tissue. Therefore, it is recommended to fully evaluate the driver genes in lymph node metastasis after radical resection.


The coexistence of EGFR mutation and ALK rearrangement in patients with lung adenocarcinomas represents a rare molecular subtype of lung cancer [1,2,3]. There were several previous studies focused on the simultaneous occurrence of ALK rearrangements and EGFR mutations in unifocal lung cancer [4,5,6]. With the widespread use of low-dose chest computed tomography (CT) and lung cancer screening, the rate of lung carcinoma patients presenting with multiple lesions have been reported from 0.2 to 20%, and most of these cases were multiple pulmonary adenocarcinoma [7]. The prevalence and clinical relevance of EGFR/ALK co-alterations in multifocal adenocarcinomas required detailed investigation as well. Our previous study showed that concomitant EGFR mutation and ALK-rearrangement in synchronous multifocal lung adenocarcinomas was more frequent [8]. Here, we reported a case of patient who diagnosed with multifocal lung adenocarcinomas exhibiting both EGFR mutation and EML4-ALK rearrangement, in order to give some helpful advices for the clinical practice.

Case presentation

A 57-year-old non-smoking woman presented to our hospital with dyspnea in July 2017. Physical examination and laboratory test results showed no significant abnormalities. The chest Computer tomography (CT) scan revealed a 3.2 cm × 3.9 cm solid nodule in the left upper lung (LUL, Fig. 1a) and a 2.3 × 1.6 cm ground glass nodule in the left lower lobe (LLL, Fig. 1f). The patient consequently underwent a LUL resection, a left lower lobe wedge resection, and VATS lymphadenectomy on July 27, 2017. Invasive adenocarcinoma in the LUL lesion was confirmed by the histopathologic examination, with mixed solid and cribriform patterns (Fig. 1b). The results of Immunohistochemistry (Fig. 1c) and fluorescent in situ hybridization (Fig. 1d) revealed that ALK rearrangement was positive. EGFR mutation was not detected by using the amplification refractory mutation system–polymerase chain reaction (ARMS-PCR, Fig. 1e). The LLL nodule also diagnosed as invasive adenocarcinoma, with predominant papillary patterns (Fig. 1g) and EGFR mutation-positive (Fig. 1j), whereas ALK rearrangement was negative (Fig. 1h and i). In addition, the results of 4/7/10/11 lymph nodes pathology confirmed tumor metastasis. NGS–based analysis displayed an ALK rearrangement (EML4 exon 13–ALK exon 20 in LUL nodule, abundance 6.42%, Fig. 1k) and EGFR 19 exon deletion in LLL lesion (c.2240_2248delTAAGAGAAG, p.L747_A750delinsS, abundance 15.58%, Fig. 1l). According to the 8th edition American Joint Committee on Cancer (AJCC) and American College of Chest Physicians Evidence-Based Clinical Practice (ACCP, 3rd edition), the lesions in LUL and LLL were defined as multiple primary adenocarcinomas. Therefore, the tumor classification should be determined separately (LUL: pT2a, LLL: pT1c). Considering the status of lymph node metastasis as N2, the patient was treated as stage 3A non-small cell lung cancer. Initially, the first-line chemotherapy with pemetrexed and nedaplatin (pemetrexed 750 mg/m2 with nedaplatin 110 mg/m2) was carried out on August 26, 2017. After 6 cycles, the CT scan showed no signs of recurrence and lymphadenectasis. Then the patient received chest radiotherapy with a dose of 54 Gy in 27 fractions. The pulmonary lesions were well controlled. Until February 11, 2019, the patient developed headache, dizziness and thoracodynia. Brain MRI detected a cranial lesion in the right occipital lobe (maximum diameter, 13 mm, Fig. 2a) and CT scan detected a bone destruction in the right posterior 12th rib (Fig. 2d and g), which indicated tumor metastasis. Based on the molecular finding, the patient was delivered the EGFR TKI gefitinib (250 mg daily) at the first. However, the headache and thoracodynia were improved after first month of target therapy. The brain lesion increased to 16 mm (Fig. 2b) and bone destruction worsened (Fig. 2e and h). The therapeutic outcome was considered as progressive disease (PD) and Gefitinib therapy was stopped. As the tumor was positive for ALK rearrangement, the patient was started on crizotinib 250 mg orally twice daily in April 2019. A local tomotherpy was administered to control the brain metastatic lesion contemporary, while no radiotherapy was given to the rib lesion. Three months after the initiation of crizotinib therapy, imaging examinations revealed obvious decreasing of the size of the brain metastases (Fig. 2c). Furthermore, the rib lesion almost disappeared and showed bony restoration (Fig. 2f and i), which was evaluated as partial remission. At the last follow-up (Dec.20, 2019), no evidence of disease progression was found and she still received crizotinib therapy. The treatment of the case suggested that the brain and rib metastasis tumor were both probably driven by ALK gene rather than EGFR. Therefore, we were very interested in the status of the driven gene in the lymph node metastasis of this case. Several tests were performed on metastatic lymph nodes, such as Immunohistochemistry, FISH and ARMS-PCR, and the results showed that all of the metastatic lymph nodes revealed a cribriform growth pattern (Fig. 3a). The pattern suggested that the positive genetic alterations was ALK rearrangement (Fig. 3b and c) rather than EGFR mutation (Fig. 3d). The histomorphology and oncogene alteration of metastatic carcinoma in lymph nodes are consistent with those in the LUL.

Fig. 1
figure 1

Imaging, pathologic and molecular characteristics of the multifocal adenocarcinoma. Computed tomography showing a solid nodule in the LUL (a) and a Ground-Glass Nodule in the LLL(F) . Microscopic showed mixed solid and cribriform patterns in the LUL nodule (b) and a Papillary Pattern in the LLL nodule (g) (HE; original magnification, × 100). c ALK protein was positively expressed in LUL nodule (c) but negative for LLL nodule (h) (immunohistochemistry; original magnification, × 100). The break-apart fluorescence in situ hybridization assay verified ALK receptor tyrosine kinase gene (ALK) rearrangement in LUL nodule (d) but not in LLL nodule (i) (FISH; original magnification, × 1000). EGFR mutations were not found in LUL nodule (e), but a deletion of EGFR exon 19 presented in LLL nodule (j) by the ARMS-PCR method. NGS test confirmed the ALK fusion(E13;A20, relative abundance 6.42%) in LUL nodule (k) and EGFR 19 exon deletion (c.2240_2248delTAAGAGAAG, p.L747_A750delinsS, relative abundance 15.58%) in LLL lesion (l)

Fig. 2
figure 2

Management of brain and rib metastasis treatment. Head MRI (2019/2/11) showed a 13 mm cranial lesion (upper panel: T2-weighted MRI) (a) and bone destruction in the right posterior 12th rib was detected by an CT scan (d and g). After 1 months of EGFR tyrosine kinase inhibitor treatment, a slight enlargement (to 16 cm) of the brain metastasis lesion (b) and bone destruction in 12th rib worsened(e and h). The patient was treated with crizotinib, brain metastatic lesion received a local tomotherpy contemporary but the rib lesion without radiotherapy. Three months after the therapy, imaging examinations revealed obvious decrease in the size of the brain metastases (c). The rib lesion almost disappeared and showed bony restoration (f and 2i)

Fig. 3
figure 3

The molecular characteristics in metastatic lymph nodes. Results of H&E Staining (a), showed mixed solid and cribriform patterns, Ventana IHC ALK (clone D5F3) (b) and ALK gene break apart probe in FISH (c), showed positive results, and negative for EGFR mutation by ARMS-PCR analysis (d)


Here we report the case presented with one mass at upper lobe and another mass in the lower lobe of left lung. For multifocal lung cancer, the distinction between multiple primaries (MPs) and intrapulmonary metastases (IMs) was of great clinical importance and challenging, as it influenced cancer staging, therapeutic strategy and outcomes [9,10,11]. After radical surgery, both masses were diagnosed as adenocarcinoma by pathological results, whereas morphological assessment revealed two distinct predominant architectural patterns. In addition, the results of molecular profiling showed that EML4-ALK rearrangement was positive in the LUL, while EGFR gene mutation was detected in the LLL. According to the 8th AJCC staging manual, genomic profiling using comparative genomic hybridization has been suggested to classify tumors effectively but could be hard to implement in routine practice [12]. Sun et al. found that comprehensive histologic assessment combined with a low-grade lepidic component was more accurate clinically and more cost-effective in distinguishing MPs from IMs. In the present case, low-grade lepidic components were identified in both lesions. Tumor in different lobe was classified as MPs according to these factors. Moreover, discrepancy of driver mutations in multiple Lung nodules was evident. From the above, tumors in LUL and LLL was classified as primary tumors and originated from different clones. Accordingly, each tumor should be assigned a separate T, N and M stage as if it were a unifocal lung cancer. In addition, the morphologic and molecular characteristic of the metastases in lymph nodes further supported that lymph node metastatic originated from the LUL lesion, which indicated that the lesion should be diagnosed with pT2aN2M0 and LLL lesion would be determined as cT1cN0M0. The patient received adjuvant chemo- therapy and radiation therapy and pulmonary lesions were well controlled without recurrence. Unfortunately, brain metastasis occurred in February 2019. It is still not frequent enough to define specific guidelines and at present it is not possible to establish the best sequence of treatments. The responses to EGFR and/or ALK inhibitors have been conflicting [4, 13, 14]. Based on the previous molecular finding, the patient was treated the EGFR-TKI. In our case, EGFR-TKI was not effective firstly, while subsequent ALK inhibitors were efficient. Despite the lack of direct evidence, we speculated that brain metastases may be driven by the ALK gene mutation. Our latest study has showed that concomitant EGFR mutation and EML4-ALK rearrangement in lung adenocarcinoma was more frequent in multifocal lesions. Interestingly, there were more lymph node metastasis in patients with multiple ALK gene fusion-positive lesions and more patients with N2 stage tumors. Furthermore, in our retrospective study, metastatic lesions in lymph node were driven by ALK rearrangement rather than EGFR mutation in four cases [6, 8]. All these results suggested that ALK probably played a key role in tumor metastasis of multifocal Lung Adenocarcinoma Harboring EGFR/ALK co-alteration.

The status of the oncogenic mutations in lymph node metastasis may provide some effective hints for metastasis lesion in other organ or tissue. Therefore, it is recommended to fully evaluate the driver genes in lymph node metastasis after radical resection. Beside, we also highlighted the importance of a good morphological approach to multiple lung adenocarcinoma because the phenotypical appearance can, probably, suggest or suspect different oncogenic alterations. Vice versa, even if in the presence of multiple lung adenocarcinoma with the same morphology, is important to test the status of oncogenic mutations in each neoplasia.

Any time, classification of the scarce cases often benefits from multidisciplinary discussion. Furthermore, we need to accumulate more cases to confirm and underlying precise mechanism remains to be clarified.

Availability of data and materials

The dataset supporting the conclusions of this article is included within the article.



Epidermal growth factor receptor


Anaplastic lymphoma kinase


Computed tomography


Next generation sequencing


tyrosine kinase inhibitor


immunohistochemical staining




  1. Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C, Sammarelli G, Thai E, Ardizzoni A. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer. 2011;71(2):241–3.

    Article  CAS  Google Scholar 

  2. Popat S, Vieira de Araujo A, Min T, Swansbury J, Dainton M, Wotherspoon A, Lim E, Nicholson AG, O'Brien ME. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thoracic Oncol. 2011;6(11):1962–3.

    Article  Google Scholar 

  3. Kuo YW, Wu SG, Ho CC, Shih JY. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thoracic Oncol. 2010;5(12):2039–40.

    Article  Google Scholar 

  4. Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, Tian HX, Xie Z, Chen HJ, Huang YS, Jiang BY, Wang Z, Wang BC, Yang XN, Zhong WZ, Nie Q, Liao RQ, Mok TS, Wu YL. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res. 2014;20(5):1383–92.

    Article  Google Scholar 

  5. Cai W, Lin D, Wu C, Li X, Zhao C, Zheng L, Chuai S, Fei K, Zhou C, Hirsch FR. Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR Coaltered lung adenocarcinoma. J Clin Oncol. 2015;33(32):3701–9.

    Article  CAS  Google Scholar 

  6. Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget. 2017;8(35):59889–900.

    Article  Google Scholar 

  7. Wang X, Wang M, MacLennan GT, Abdul-Karim FW, Eble JN, Jones TD, Olobatuyi F, Eisenberg R, Cummings OW, Zhang S, Lopez-Beltran A, Montironi R, Zheng S, Lin H, Davidson DD, Cheng L. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst. 2009;101(8):560–70.

    Article  CAS  Google Scholar 

  8. Fan J, Dai X, Wang Z, Huang B, Shi H, Luo D, Zhang J, Cai W, Nie X, Hirsch FR. Concomitant EGFR mutation and EML4-ALK rearrangement in lung adenocarcinoma is more frequent in multifocal lesions. Clin Lung Cancer. 2019;20(4):e517–30.

    Article  CAS  Google Scholar 

  9. Schneider F, Derrick V, Davison JM, Strollo D, Incharoen P, Dacic S. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. Modern Pathol. 2016;29(7):735–42.

    Article  CAS  Google Scholar 

  10. Wu C, Zhao C, Yang Y, He Y, Hou L, Li X, Gao G, Shi J, Ren S, Chu H, Zhou C, Zhang J, Schmid-Bindert G. High discrepancy of driver mutations in patients with NSCLC and synchronous multiple lung ground-glass nodules. J Thoracic Oncol. 2015;10(5):778–83.

    Article  CAS  Google Scholar 

  11. Girard N, Ostrovnaya I, Lau C, Park B, Ladanyi M, Finley D, Deshpande C, Rusch V, Orlow I, Travis WD, Pao W, Begg CB. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res. 2009;15(16):5184–90.

    Article  CAS  Google Scholar 

  12. Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e369S–99S.

    Article  Google Scholar 

  13. Won JK, Keam B, Koh J, Cho HJ, Jeon YK, Kim TM, Lee SH, Lee DS, Kim DW, Chung DH. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Ann Oncol. 2015;26(2):348–54.

    Article  CAS  Google Scholar 

  14. Fan J, Dai X, Nie X. Concomitant epidermal growth factor receptor mutation and EML4-ALK fusion in a patient with multifocal lung adenocarcinomas. J Thorac Oncol. 2018;13(3):e45–8.

    Article  Google Scholar 

Download references


This work was sponsored by Shanghai Tongshu Biotechnology Co., Ltd.


This study was supported by the National Natural Science Foundation of China (No. 81101548 and No. 81773022) and the Natural Science Foundation of Guangdong Province (No. 2016A030313070).

Author information

Authors and Affiliations



JF and JHW contributed equally as co-first authors in collecting clinical data and writing the paper. YLZ provided H&E staining images. BH performed the immunohistochemistry and molecular staining experiments. HSS provided imaging and clinical information. XN and XFD designed the study. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Xiaofang Dai or Xiu Nie.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fan, J., Wu, J., Huang, B. et al. Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report. Diagn Pathol 15, 42 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: